systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»10.26442/2075-082X_2018.3.11-13systhiper-552Research ArticleСТАТЬИARTICLESРезистентная и рефрактерная артериальные гипертонии: сходства и различия, новые подходы к диагностике и лечениюResistant and refractory arterial hypertension: similarities and differences, new approaches to diagnosis and treatmentАксеноваА. В.AksenovaA. V.ksenovaannav@gmail.comЕсауловаТ. Е.EsaulovaT. E.yestatyana@gmai.comСиваковаО. А.SivakovaO. A.ya.olga-siv2012@ya.ruЧазоваИ. Е.ChazovaI. E.c34h@yandex.ruФГБУ «НМИЦ кардиологии»РоссияNational Medical Research Center of Cardiologyof the Ministry of Health of the Russian FederationRussian Federation2018231220221531113Copyright © Аксенова А.В., Есаулова Т.Е., Сивакова О.А., Чазова И.Е., 20222022Аксенова А.В., Есаулова Т.Е., Сивакова О.А., Чазова И.Е.Aksenova A.V., Esaulova T.E., Sivakova O.A., Chazova I.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/552

Рефрактерная артериальная гипертония (АГ) - особый фенотип АГ, устойчивый к проводимой антигипертензивной терапии. Термины «рефрактерная АГ» и «резистентная АГ» зачастую считают взаимозаменяемыми и используют в отношении АГ, трудно поддающейся лечению. Группа пациентов с рефрактерной АГ, т.е. больных, не достигающих целевых цифр артериального давления на фоне максимальной антигипертензивной терапии, очень мала. Настоящий обзор посвящен сравнению сходных и контрастных черт в определениях, частоте встречаемости, характеристике пациентов, факторах риска и возможных этиологиях.

Refractory hypertension is a novel phenotype of antihypertensive treatment failure. The terms "refractory hypertension" and "resistant hypertension" were considered interchangeable for a long time and related to difficult-to-treat hypertension. Recently, the term "refractory hypertension" refers to a very small group of patients who do not really reach the target blood pressure for maximum antihypertensive therapy. In this review we discuss similarities and contrasts definition, prevalence, patient characteristics, risk factors, and possible underlying etiologies of refractory and resistant hypertension.

рефрактерная артериальная гипертониярезистентная артериальная гипертонияантигипертензивная терапияrefractory hypertensionresistant hypertensionantihypertensive therapyReferencesCalhoun D.A, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51 (6): 1403-19.Calhoun D.A, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51 (6): 1403-19.Aelajado M.C, Pisoni R, Dudenbostel T et al. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich) 2012; 14: 7-12. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults.Aelajado M.C, Pisoni R, Dudenbostel T et al. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich) 2012; 14: 7-12. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults.Dudenbostel T, Calhoun D. Refractory Hypertension a novel phenotype of antihypertensive treatment failure. Hypertension 2016; 67: 1085-92.Dudenbostel T, Calhoun D. Refractory Hypertension a novel phenotype of antihypertensive treatment failure. Hypertension 2016; 67: 1085-92.Диагностика и лечение артериальной гипертонии (клинические рекомендации). Кардиологический вестник. 2015; Х (1).Диагностика и лечение артериальной гипертонии (клинические рекомендации). Кардиологический вестник. 2015; Х (1).Dudenbostel T, Acelajado M.C, Pisoni R et al. Refractory hypertension: evidence of heightened sympathetic activity as a cause of antihypertensive treatment failure. Hypertension 2015; 66: 126-33.Dudenbostel T, Acelajado M.C, Pisoni R et al. Refractory hypertension: evidence of heightened sympathetic activity as a cause of antihypertensive treatment failure. Hypertension 2015; 66: 126-33.De la Sierra A et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57 (5): 898-902.De la Sierra A et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57 (5): 898-902.Muntner P et al. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2014; 64 (5): 1012-21.Muntner P et al. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2014; 64 (5): 1012-21.Calhoun D.A, Booth J.N, Oparil S et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension 2014; 63: 451-8.Calhoun D.A, Booth J.N, Oparil S et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension 2014; 63: 451-8.Чазова И.Е., Данилов Н.М., Литвин А.Ю. Рефрактераня артериальная гипертония. Монография. М.: Атмосфера, 2014.Чазова И.Е., Данилов Н.М., Литвин А.Ю. Рефрактераня артериальная гипертония. Монография. М.: Атмосфера, 2014.Velasco A, Siddiqui M, Kreps E et al. Refractory hypertension is not attributable to intravascular fluid retention as determined by intracardiac volumes. Hypertension 2018.Velasco A, Siddiqui M, Kreps E et al. Refractory hypertension is not attributable to intravascular fluid retention as determined by intracardiac volumes. Hypertension 2018.Irvin M.R, Booth J.N, Shimbo D et al. Calhoun/Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality. J Am Soc Hypertens 2014; 8: 405-13.Irvin M.R, Booth J.N, Shimbo D et al. Calhoun/Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality. J Am Soc Hypertens 2014; 8: 405-13.Armario P, Oliveras A, Blanch P et al. Refractory hypertension: prevalence, associated factors and differences with resistant hypertension. J Hypertension 2017. DOI: 10.1097/01.hjh.0000523892.30290.ddArmario P, Oliveras A, Blanch P et al. Refractory hypertension: prevalence, associated factors and differences with resistant hypertension. J Hypertension 2017. DOI: 10.1097/01.hjh.0000523892.30290.ddModolo R, de Faria A.P, Sabbatini A.R et al. Refractory and resistant hypertension: characteristics and differences observed in a specialized clinic. J Am Soc Hypertens 2015; 9: 397-402.Modolo R, de Faria A.P, Sabbatini A.R et al. Refractory and resistant hypertension: characteristics and differences observed in a specialized clinic. J Am Soc Hypertens 2015; 9: 397-402.Gaddam K.K et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008; 168 (11): 1159-64.Gaddam K.K et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008; 168 (11): 1159-64.Dudenbostel T, Siddiqui M, Gharpure N, Calhoun D. Refractory versus resistant hypertension: Novel distinctive phenotypes. J Nat Sci 2017; 3 (9): e430.Dudenbostel T, Siddiqui M, Gharpure N, Calhoun D. Refractory versus resistant hypertension: Novel distinctive phenotypes. J Nat Sci 2017; 3 (9): e430.

The authors declare that there are no conflicts of interest present.